2009 Fiscal Year Final Research Report

Pharmacogenetic research of individual differences in the occurrence of Paroxetine discontinuation syndrome.

Research Project

Project/Area Number	20790405
Research Category	Grant-in-Aid for Young Scientists (B)
Allocation Type	Single-year Grants
Research Field	Applied pharmacology
Research Institution	Fukuoka University
Principal Investigator	MURATA Yusuke Fukuoka University, 薬学部, 助教 (90461508)
Project Period (FY)	2008 – 2009
Keywords	選択的セロトニン再取込阻害薬 / パロキセチン / 大うつ病性障害 / 離脱症状 / 薬理遺伝学
Research Abstract	Paroxetine, a selective serotonin reuptake inhibitor (SSRI), has now become the first-line treatment for depression and anxiety disorder. However, discontinuation syndrome following abrupt withdrawal or dose reduction of SSRIs has been recently documented. There are no studies with regard to assess the relation of SSRI discontinuation syndrome and gene polymorphisms. In this study, we investigated the effect of the serotonin-related genetic polymorphisms on the occurrence of paroxetine discontinuation syndrome. In conclusion, the abrupt stoppage of medication is a major risk factor for the occurrence of paroxetine discontinuation syndrome. In addition, the C(-1019)G polymorphism of the 5-HT1A receptor gene may be related to the occurrence of paroxetine discontinuation syndrome.

(2 results)